Revista de Senologia y Patologia Mamaria最新文献

{"title":"The role of AI and virtual environments in the Future Breast Unit","authors":"Rogelio Andrés-Luna ,&nbsp;Josep Salvador López ,&nbsp;Pedro Gouveia","doi":"10.1016/j.senol.2024.100661","DOIUrl":"10.1016/j.senol.2024.100661","url":null,"abstract":"<div><div>Artificial intelligence (AI) has offered significant advances in medicine from its beginnings, with expert systems that complemented decision-making, to its current use, present in many applications where we are not fully aware. In this article, we are going to review and analyse different real uses of AI, which will enable us to correctly frame the vectors of present and future applications. From those already known in management, assistance in decision-making, radiomics, or pathomics to more recent ones such as virtual and augmented reality, remote monitoring, or the prediction of morphological results after surgery. Over time, the development of machine learning algorithms and the exponential increase of available health data will allow AI to provide more accurate and personalised diagnoses, development of new therapies and drugs, significantly reducing research and testing times. For this to be possible, greater communication and cooperation between healthcare professionals and the world of engineering will be necessary, starting in the educational field where there is a need to train professionals in engineering and biomedicine capable of tackling challenges with a complete vision, thus reducing the wall of technical understanding and deepening the development of useful applications.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 2","pages":"Article 100661"},"PeriodicalIF":0.3,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143445033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cáncer de mama en mujeres mayores de 80 años: tratamiento primario","authors":"Leyre Marco Sanz,&nbsp;Sara del Olmo Bautista,&nbsp;Henar Sánchez Quirós,&nbsp;Yolanda Pérez Martínez,&nbsp;Sergio Gutiérrez García,&nbsp;Verónica Palomo Cabañes,&nbsp;Marta Robles Gaitero,&nbsp;María Purificación Martínez del Val,&nbsp;Teodora Alonso Gutiérrez,&nbsp;Modesto Rey Novoa","doi":"10.1016/j.senol.2025.100666","DOIUrl":"10.1016/j.senol.2025.100666","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objetivo&lt;/h3&gt;&lt;div&gt;analizar el tipo de tratamiento primario que reciben pacientes mayores de 80 años en un intervalo de 6 años.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Material y método&lt;/h3&gt;&lt;div&gt;se ha realizado un estudio observacional retrospectivo en pacientes mayores de 80 años diagnosticadas de cáncer de mama, de 2017 a 2022. Se recogieron datos sobre el tipo de tratamiento, cirugía, características histológicas, estadio y calidad de vida.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Resultados&lt;/h3&gt;&lt;div&gt;se obtuvieron datos de un total de 188 pacientes. Edad media de 85 años. El 38,3% eran dependientes para actividades básicas de la vida diaria. Un 73,4% presentaban positividad para receptores estrogénicos y HER2 negativo. Un 75,5% recibió cirugía como tratamiento primario, un 11,1% recibió hormonoterapia, un 3,1% tratamiento con quimioterapia y un 10,1% no recibieron ningún tipo de tratamiento. El 22,3% se encontraban en estadio I. El 13,2% fueron diagnosticadas en estadio avanzado. A un 33,5% se le realizó una biopsia selectiva de ganglio centinela (BSGC).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusiones&lt;/h3&gt;&lt;div&gt;según nuestros datos analizados, existe un considerable número de pacientes que han recibido un tratamiento primario más agresivo (mastectomía y BSGC) sin beneficios en la supervivencia general a pesar de que, actualmente, existen datos que apoyan que la omisión de la evaluación axilar quirúrgica o, incluso, la radioterapia después de cirugía conservadora, no afecta la supervivencia general en mujeres de 70 años o más con enfermedad en estadio clínico temprano, receptor hormonal positivo y HER2 negativo.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;Analyzing the type of primary treatment that patients aged over 80 years receive within a 6-year interval.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and method&lt;/h3&gt;&lt;div&gt;An observational retrospective study was conducted in patients aged over 80 years who were diagnosed with breast cancer between 2017 to 2022. Data were collected on the type of primary treatment, surgery, histological characteristics of tumors, stage and quality of life.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Information was taken from 188 patients. The average age was 85 years old. A 38,3% were dependent for Basic Activities of Daily Living, 73,4% tested positive for estrogen receptors and negative HER2, 75,5% underwent surgery as primary treatment, 11,1% received hormone therapy, 3,1% received chemotherapy treatment, and 10,1% did not undergo any type of treatment; 22,3% of patients were in stage I. A 13,2% were diagnosed at an advanced stage, and 33,5% underwent selective sentinel lymph node biopsy (SSNB).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusión&lt;/h3&gt;&lt;div&gt;According to our analyzed data, there is a considerable number of patients who have undergone a more aggressive primary treatment (mastectomy and SSNB) without benefits in overall survival, despite evidence supporting that omitting surgical axillary evaluation or even radiotherapy after conservative surgery does not affect overall survival in women a","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100666"},"PeriodicalIF":0.3,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143299284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlación entre la carga tumoral total de los ganglios linfáticos analizada mediante One Step Nucleic Acid Amplification (OSNA) y la decisión de realizar una linfadenectomía axilar en el cáncer de mama temprano","authors":"Paula Chamocho Lloro ,&nbsp;María Dolores Rodríguez Garnica ,&nbsp;Beatriz Sánchez Jimenez ,&nbsp;Sergio Rodriguez Lobalzo ,&nbsp;Angel Calvo Tudela ,&nbsp;Alejandro J. Rohde Calleja ,&nbsp;Francisco Rivas Ruiz ,&nbsp;José C. Maañón di Leo","doi":"10.1016/j.senol.2025.100667","DOIUrl":"10.1016/j.senol.2025.100667","url":null,"abstract":"<div><h3>Introduction</h3><div>The aim of this study was to determine the correlation between total lymph load (TLL) analyzed by one step nucleic acid amplification (OSNA) and the results obtained in our clinical practice, and whether TTL is a useful tool for selecting patients who should undergo axillary lymph node dissection.</div></div><div><h3>Material and methods</h3><div>The study has a retrospective cohort design, conducted at the Hospital Costa de Sol on 92 patients with (GC<!--> <!-->+) analyzed by OSNA, between 2012 and 2017.</div></div><div><h3>Results</h3><div>Disease-free survival was analyzed classifying patients into micro-metastatic, macro-metastatic with less than 25,000 copies of mRNA-CK19/ul, and macro-metastatic with more than 25,000 copies of mRNA-CK19/ul, with no statistical significance found between groups (log-rank test 0.266266).</div></div><div><h3>Discussion</h3><div>The recommendation of axillary lymph node dissection (ALND) in conservatively operated patients with clinically (or radiologically) negative axilla and high tumor load as determined by OSNA is not related to local disease control.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 2","pages":"Article 100667"},"PeriodicalIF":0.3,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143341654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Del Ars Magna a la inteligencia artificial generativa","authors":"Rafael Berlanga Llavori","doi":"10.1016/j.senol.2024.100663","DOIUrl":"10.1016/j.senol.2024.100663","url":null,"abstract":"<div><div>This article aims to present the key elements in the evolution of Artificial Intelligence (AI) in recent years, especially Generative Artificial Intelligence. Predictive or discriminative AI has had a notable impact on medicine in the last two decades, especially in the diagnosis of pathologies based on clinical data. Now, generative AI leads us to new challenges and opportunities in numerous fields such as personalised treatment, prevention, pro-action, new therapeutic techniques and, in general, the broadening of the horizons of clinical and biomedical research. For this work, we have carried out a bibliographic study and organised it into the main ideas for the application of generative AI to medicine. The main result of this study is a set of potential applications of generative AI that are being initiated in several areas of medicine and that may lead to a revolution in medicine in the short to mid-term. However, there are major hurdles to overcome, mainly those concerning the quality and accuracy of these systems, as well as the privacy and ethical barriers that must be respected by the new automated healthcare systems.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100663"},"PeriodicalIF":0.3,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143132587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¿Es posible realizar la biopsia selectiva de ganglio centinela (BSGC) en una paciente con mastectomía preservadora de piel y pezón? Descripción de un caso","authors":"Miriam Alcaide Lucena ,&nbsp;Carlos José Rodríguez González ,&nbsp;Rafael Nieto Serrano ,&nbsp;Jesús García Rubio ,&nbsp;Benito Mirón Pozo","doi":"10.1016/j.senol.2025.100665","DOIUrl":"10.1016/j.senol.2025.100665","url":null,"abstract":"<div><div>BRCA mutation carriers have an increased risk of breast cancer. Among the risk-reducing measures is prophylactic bilateral mastectomy. In less than 1%  of BRCA patients undergoing this surgery, previously undetected breast cancer is found. Routine sentinel lymph node biopsy has not shown benefit because few patients have occult cancer, and it is a technique that also involves morbidity. If a carcinoma is found in the specimen, axillary staging should be done in a second procedure, which has traditionally been performed with lymphadenectomy due to the absence of breast tissue and the belief that sentinel lymph node biopsy (SLNB) is not feasible. We present the case of a patient diagnosed with an infiltrating tumor in the left mastectomy specimen, and successful SLNB performed in a second procedure. Four nodes were sent for intraoperative analysis with negative results. Axillary lymphadenectomy was avoided, achieving proper axillary staging. It is technically feasible to perform SLNB after a skin- and nipple-sparing mastectomy, avoiding systematic axillary lymphadenectomy for staging in these patients, thus avoiding the morbidity associated with this technique.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 2","pages":"Article 100665"},"PeriodicalIF":0.3,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143141960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cáncer de mama bilateral sincrónico en el varón. Descripción de un caso y revisión de la bibliografía","authors":"Noelia Lete Aguirre,&nbsp;Jorge Martínez Medel,&nbsp;Antonio Tomás Güemes Sánchez","doi":"10.1016/j.senol.2024.100664","DOIUrl":"10.1016/j.senol.2024.100664","url":null,"abstract":"<div><div>Male breast cancer is a rare entity, accounting for less than 1% of all diagnosed breast cancers. Risk factors include advanced age, obesity, testicular and liver diseases, and the presence of germline BRCA2 mutations. Even rarer is the occurrence of synchronous bilateral breast tumors, defined as tumors diagnosed within 12 months of the initial breast cancer. Due to its extreme rarity, few cases have been published in recent years, with most not referencing mutation studies. Greater awareness of the disease would prevent delays in both diagnosis and treatment.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 2","pages":"Article 100664"},"PeriodicalIF":0.3,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143141963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can we use HER2DX to modulate treatment intensity in HER2 positive early breast cancer?","authors":"Beatriz Alonso De Castro ,&nbsp;Cristina Reboredo Rendo ,&nbsp;Fernanda Mosele ,&nbsp;Eva Pérez López ,&nbsp;Lourdes Calvo Martínez ,&nbsp;Silvia Antolín Novoa","doi":"10.1016/j.senol.2024.100659","DOIUrl":"10.1016/j.senol.2024.100659","url":null,"abstract":"<div><div>Clinical HER2 positive (cHER2<!--> <!-->+) breast cancer (BC) is an heterogenous disease, which represents a major challenge in the design of personalized therapeutic strategies. In recent years, a great development against HER2 targeted therapies took place, but not all patients benefit from the same regimens. In this context, it is essential to develop genomic analysis, with clinicopathological and molecular biomarkers, as HER2DX, in order to improve response, safety, and patient's quality of life. This review aims to comprehensively summarize the current evidence regarding the development, validation, and application of HER2DX score in clinical practice. Genomic development and clinical application in the identification of different cHER2<!--> <!-->+ BC populations are discussed, along as future changing strategies for escalation and de-escalation treatments.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100659"},"PeriodicalIF":0.3,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143132585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accelerating cancer diagnostics: A novel AI pipeline for efficient histopathological image analysis","authors":"David Anglada-Rotger ,&nbsp;Sonia Rabanaque-Rodríguez ,&nbsp;Laura Sáez-Parés ,&nbsp;Jordi Temprana-Salvador","doi":"10.1016/j.senol.2024.100662","DOIUrl":"10.1016/j.senol.2024.100662","url":null,"abstract":"<div><div>The surge in digital pathology and the vast amount of data from whole slide images (WSIs) have made it essential to develop tools that can efficiently analyze and support cancer diagnosis. An innovative artificial intelligence-based pipeline has been developed to tackle this challenge, significantly speeding up and enhancing the accuracy of breast cancer diagnosis. Created within the DigiPatICS project, in partnership with 8 hospitals across Catalonia, Spain, this pipeline begins by identifying tissue areas in WSIs and breaking them down into smaller, manageable tiles. Using smart image processing techniques, it filters out tiles that do not contain relevant information and focuses on the essential ones. Advanced deep learning algorithms then work to identify and classify different types of cells within the tissue. Proven effective on key breast cancer markers like HER2, Ki67, ER, and PR, the system precomputes the results overnight, allowing pathologists to simply load the pre-analyzed data for the areas of interest of the WSI that they select during their workday. Each WSI is analyzed in more or less 1110 s, providing reliable results that are ready when needed. Now, an integral part of routine workflows, this approach is revolutionizing how breast cancer slides are processed, enhancing diagnostic capabilities, and reshaping digital pathology.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100662"},"PeriodicalIF":0.3,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143132586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Descripcion de un caso de carcinoma papilar encapsulado apocrino de mama: un dilema diagnóstico","authors":"José Richard Tenazoa-Villalobos ,&nbsp;Edgar Fermín Yan-Quiroz ,&nbsp;Gladys Llerena-Cobián","doi":"10.1016/j.senol.2024.100653","DOIUrl":"10.1016/j.senol.2024.100653","url":null,"abstract":"<div><div>Encapsulated papillary carcinoma of the breast with apocrine differentiation is an extremely rare neoplasm that possesses both an encapsulated papillary configuration as well as epithelial cells that differentiated apocrine. It is not included as such in the fifth edition of the World Health Organization (WHO) classification of tumors because there are no research studies on the subject. These neoplasms have cells that are distinguished by having granular cytoplasm, large nuclei with prominent nucleoli, through immunohistochemistry these tumors are negative for estrogen, progesterone and HER2 receptors, but despite the absence of these markers and the nuclear atypia described, they have an overall survival that exceeds 5 years compared even to the other types of triple-negative breast neoplasm. We present the case of an 85-year-old woman who presented a right breast tumor that was classified as apocrine encapsulated papillary carcinoma, underwent right total mastectomy surgery and allowed the control of the disease, thus achieving a favorable outcome.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 2","pages":"Article 100653"},"PeriodicalIF":0.3,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143141961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Los colgajos de perforantes en la cirugía del cáncer de mama","authors":"Ricardo Pardo Garcia","doi":"10.1016/j.senol.2024.100660","DOIUrl":"10.1016/j.senol.2024.100660","url":null,"abstract":"","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 1","pages":"Article 100660"},"PeriodicalIF":0.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143161086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}